JPMorgan Chase & Co. Issues Pessimistic Forecast for Illumina (NASDAQ:ILMN) Stock Price

Illumina (NASDAQ:ILMN) had its target price decreased by investment analysts at JPMorgan Chase & Co. from $320.00 to $300.00 in a research report issued on Friday, Benzinga reports. The brokerage currently has an “overweight” rating on the life sciences company’s stock. JPMorgan Chase & Co.‘s price objective would indicate a potential upside of 27.12% from the stock’s current price.

A number of other equities analysts also recently issued reports on the company. Evercore restated an “underperform” rating on shares of Illumina in a research report on Friday. Wall Street Zen raised Illumina from a “hold” rating to a “buy” rating in a research note on Sunday, October 11th. Deutsche Bank Aktiengesellschaft cut Illumina to a “hold” rating in a report on Wednesday, August 5th. Argus increased their target price on shares of Illumina from $180.00 to $235.00 and gave the company a “buy” rating in a research report on Thursday, September 3rd. Finally, Weiss Ratings restated a “hold (c)” rating on shares of Illumina in a report on Monday, August 31st. Nine research analysts have rated the stock with a Buy rating, seven have assigned a Hold rating and three have issued a Sell rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Hold” and an average price target of $238.53.

Illumina Trading Down 18.6%

NASDAQ:ILMN traded down $54.07 during mid-day trading on Friday, hitting $235.99. 5,389,541 shares of the company’s stock were exchanged, compared to its average volume of 2,178,200. The company has a 50 day simple moving average of $249.30 and a 200-day simple moving average of $176.18. The company has a current ratio of 1.80, a quick ratio of 1.40 and a debt-to-equity ratio of 0.53. Illumina has a fifty-two week low of $106.12 and a fifty-two week high of $309.35. The firm has a market capitalization of $35.63 billion, a P/E ratio of 44.03, a PEG ratio of 4.09 and a beta of 1.41.

Illumina (NASDAQ:ILMN) last announced its quarterly earnings results on Thursday, October 29th. The life sciences company reported $1.62 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.36 by $0.26. Illumina had a net margin of 18.36% and a return on equity of 29.84%. The firm had revenue of $1.17 billion during the quarter, compared to analysts’ expectations of $1.15 billion. During the same period in the prior year, the company posted $1.34 EPS. The company’s revenue was up 4.2% on a year-over-year basis. As a group, research analysts expect that Illumina will post 5.36 earnings per share for the current year.

Insider Transactions at Illumina

In other Illumina news, Director Keith Meister sold 457,858 shares of the firm’s stock in a transaction on Tuesday, August 4th. The shares were sold at an average price of $200.10, for a total value of $91,617,385.80. Following the completion of the sale, the director directly owned 2,372,694 shares in the company, valued at approximately $474,776,069.40. This trade represents a 16.18% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Insiders have sold 2,061,235 shares of company stock worth $436,356,102 over the last 90 days. 2.90% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Illumina

Several institutional investors have recently made changes to their positions in ILMN. BlackRock Inc. bought a new position in Illumina in the 2nd quarter valued at about $3,374,423,000. WCM Investment Management LLC boosted its stake in Illumina by 45.5% during the 1st quarter. WCM Investment Management LLC now owns 5,923,173 shares of the life sciences company’s stock valued at $715,579,000 after purchasing an additional 1,851,848 shares during the last quarter. Primecap Management Co. CA bought a new stake in Illumina during the 2nd quarter worth approximately $617,981,000. Ninety One UK Ltd raised its stake in shares of Illumina by 37,920.0% in the third quarter. Ninety One UK Ltd now owns 1,359,974 shares of the life sciences company’s stock worth $372,198,000 after purchasing an additional 1,356,397 shares during the last quarter. Finally, Jupiter Topco LLC purchased a new stake in shares of Illumina in the second quarter worth approximately $358,652,000. Institutional investors and hedge funds own 89.42% of the company’s stock.

Key Stories Impacting Illumina

Here are the key news stories impacting Illumina this week:

• Positive Sentiment: Adjusted earnings exceeded expectations. Illumina reported third-quarter adjusted EPS of $1.44, above the $1.36 consensus estimate, while revenue increased 4.2% year over year to approximately $1.13 billion. Illumina Reports Financial Results for Third Quarter
• Positive Sentiment: Full-year guidance was raised. Management increased its 2026 outlook, with revenue guidance of roughly $4.65 billion at the midpoint, supported by clinical sequencing demand and continued adoption of the NovaSeq X platform. ILMN Q3 Earnings Call Highlights
• Positive Sentiment: Long-term industry demand remains favorable. Recent market reports point to strong growth in clinical genomics, sequencing-as-a-service, population screening, and AI-enabled genomic analysis—markets in which Illumina is a major participant. These reports are industry forecasts rather than new company contracts or financial commitments.
• Neutral Sentiment: Analyst sentiment became more cautious. JPMorgan reduced its price target from $320 to $300, while Robert W. Baird maintained a Hold rating. The target cut suggests less near-term upside following Illumina’s substantial prior rally. JPMorgan Adjusts Price Target
• Negative Sentiment: Revenue performance disappointed investors. Although earnings surpassed estimates, quarterly revenue was below consensus in several reports, highlighting softer demand than expected and limiting the impact of the profit beat.
• Negative Sentiment: China exposure, tariffs, and business mix remain concerns. Investors are worried about China-related revenue challenges, tariff uncertainty, research-market weakness, and pricing pressure. A broader pullback in AI-linked technology stocks also hurt sentiment toward Illumina. Illumina Shares Tumble on China Woes

About Illumina

Illumina, Inc is a biotechnology company that develops and manufactures genomics and genetic-analysis technologies. Its products are used to study DNA and RNA in applications including biomedical research, clinical testing, pharmaceutical development, reproductive health, oncology and population genomics.

The company’s offerings include next-generation sequencing systems, consumable flow cells and reagent kits, microarrays, and genomic data-analysis software. Its sequencing portfolio includes instruments such as the NovaSeq, NextSeq, MiSeq and iSeq platforms, while its informatics products include the DRAGEN platform, which supports the processing and interpretation of sequencing data.